PortfoliosLab logoPortfoliosLab logo
IMMX vs. AXTI
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Financials

Performance

IMMX vs. AXTI - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Immix Biopharma, Inc. (IMMX) and AXT, Inc. (AXTI). The values are adjusted to include any dividend payments, if applicable.

Loading graphics...

IMMX vs. AXTI - Yearly Performance Comparison


2026 (YTD)20252024202320222021
IMMX
Immix Biopharma, Inc.
74.19%137.73%-68.21%202.18%-35.67%-3.00%
AXTI
AXT, Inc.
248.50%653.46%-9.58%-45.21%-50.28%12.52%

Fundamentals

EPS

IMMX:

-$0.76

AXTI:

-$0.48

Total Revenue (TTM)

IMMX:

$0.00

AXTI:

$88.33M

Gross Profit (TTM)

IMMX:

$0.00

AXTI:

$11.24M

EBITDA (TTM)

IMMX:

-$23.69M

AXTI:

-$14.38M

Returns By Period

In the year-to-date period, IMMX achieves a 74.19% return, which is significantly lower than AXTI's 248.50% return.


IMMX

1D
6.18%
1M
12.89%
YTD
74.19%
6M
335.89%
1Y
442.26%
3Y*
71.06%
5Y*
10Y*

AXTI

1D
8.06%
1M
50.34%
YTD
248.50%
6M
1,169.04%
1Y
3,941.13%
3Y*
142.82%
5Y*
35.86%
10Y*
36.43%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Immix Biopharma, Inc.

AXT, Inc.

Return for Risk

IMMX vs. AXTI — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

IMMX
IMMX Risk / Return Rank: 9797
Overall Rank
IMMX Sharpe Ratio Rank: 9999
Sharpe Ratio Rank
IMMX Sortino Ratio Rank: 9797
Sortino Ratio Rank
IMMX Omega Ratio Rank: 9494
Omega Ratio Rank
IMMX Calmar Ratio Rank: 9999
Calmar Ratio Rank
IMMX Martin Ratio Rank: 9898
Martin Ratio Rank

AXTI
AXTI Risk / Return Rank: 100100
Overall Rank
AXTI Sharpe Ratio Rank: 100100
Sharpe Ratio Rank
AXTI Sortino Ratio Rank: 9999
Sortino Ratio Rank
AXTI Omega Ratio Rank: 9999
Omega Ratio Rank
AXTI Calmar Ratio Rank: 100100
Calmar Ratio Rank
AXTI Martin Ratio Rank: 100100
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

IMMX vs. AXTI - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Immix Biopharma, Inc. (IMMX) and AXT, Inc. (AXTI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


IMMXAXTIDifference

Sharpe ratio

Return per unit of total volatility

4.90

32.68

-27.78

Sortino ratio

Return per unit of downside risk

3.93

6.95

-3.03

Omega ratio

Gain probability vs. loss probability

1.48

1.86

-0.38

Calmar ratio

Return relative to maximum drawdown

10.94

102.50

-91.56

Martin ratio

Return relative to average drawdown

25.33

305.89

-280.56

IMMX vs. AXTI - Sharpe Ratio Comparison

The current IMMX Sharpe Ratio is 4.90, which is lower than the AXTI Sharpe Ratio of 32.68. The chart below compares the historical Sharpe Ratios of IMMX and AXTI, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Loading graphics...

Sharpe Ratios by Period


IMMXAXTIDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

4.90

32.68

-27.78

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.40

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.46

Sharpe Ratio (All Time)

Calculated using the full available price history

0.22

0.08

+0.14

Correlation

The correlation between IMMX and AXTI is 0.14, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


Dividends

IMMX vs. AXTI - Dividend Comparison

Neither IMMX nor AXTI has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

IMMX vs. AXTI - Drawdown Comparison

The maximum IMMX drawdown since its inception was -88.89%, smaller than the maximum AXTI drawdown of -98.57%. Use the drawdown chart below to compare losses from any high point for IMMX and AXTI.


Loading graphics...

Drawdown Indicators


IMMXAXTIDifference

Max Drawdown

Largest peak-to-trough decline

-88.89%

-98.57%

+9.68%

Max Drawdown (1Y)

Largest decline over 1 year

-39.84%

-36.59%

-3.25%

Max Drawdown (5Y)

Largest decline over 5 years

-90.65%

Max Drawdown (10Y)

Largest decline over 10 years

-92.45%

Current Drawdown

Current decline from peak

-18.08%

-16.74%

-1.34%

Average Drawdown

Average peak-to-trough decline

-60.48%

-82.78%

+22.30%

Ulcer Index

Depth and duration of drawdowns from previous peaks

17.21%

12.26%

+4.95%

Volatility

IMMX vs. AXTI - Volatility Comparison

The current volatility for Immix Biopharma, Inc. (IMMX) is 27.27%, while AXT, Inc. (AXTI) has a volatility of 49.61%. This indicates that IMMX experiences smaller price fluctuations and is considered to be less risky than AXTI based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading graphics...

Volatility by Period


IMMXAXTIDifference

Volatility (1M)

Calculated over the trailing 1-month period

27.27%

49.61%

-22.34%

Volatility (6M)

Calculated over the trailing 6-month period

64.64%

100.03%

-35.39%

Volatility (1Y)

Calculated over the trailing 1-year period

91.11%

122.61%

-31.50%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

110.66%

91.12%

+19.54%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

110.66%

79.43%

+31.23%

Financials

IMMX vs. AXTI - Financials Comparison

This section allows you to compare key financial metrics between Immix Biopharma, Inc. and AXT, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0010.00M20.00M30.00M40.00MAprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober0
23.04M
(IMMX) Total Revenue
(AXTI) Total Revenue
Values in USD except per share items